tradmap

LMAT Financials Lemaitre Vascular Inc

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 14.0% per year over the past 5 years.
  • Net income has grown faster than revenue (22.1% vs 14.0% per year).
  • Operating margin has expanded, at 27.2% in the latest year.
  • Free cash flow has grown 18.5% per year over the past 5 years.

Financial health

  • Operating income covered interest expense 13× in the latest year, down from 22× 5 years ago.

Shareholder returns

  • Dividends have been paid for 15 consecutive years, consuming 31.4% of earnings and 24.3% of free cash flow.
  • The dividend has grown 18.7% per year over the past 5 years.
Revenue & net income
$0 $125M $250M 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 36% 72% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
0% 9% 18% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
$0 $37M $74M 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $14M $28M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$200M -$21M $158M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $250M $58M 71.5% 27.2% 14.7% 9.4% $74M $28M
2024 $220M $44M 68.6% 23.8% 13.0% 8.0% $37M $26M
2023 $193M $30M 65.7% 19.0% 10.1% 8.7% $29M $24M
2022 $162M $21M 64.9% 16.6% 7.7% 6.6% $22M $19M
2021 $154M $27M 65.7% 23.6% 10.6% 9.2% $30M $14M
2020 $129M $21M 65.4% 22.3% 12.3% 8.4% $32M $27M
2019 $117M $18M 68.1% 18.1% 12.1% 9.5% $10M $12M
2018 $106M $23M 70.0% 26.7% 17.6% 15.0% $16M $26M
2017 $101M $17M 70.1% 20.9% 15.6% 13.6% $16M $19M
2016 $11M 12.1% 10.4% $14M $24M
2015 $8M 10.0% 8.6% $27M
2014 $4M 5.7% 4.8% $19M
2013 $3M 5.7% 4.5% $15M
2012 $3M 4.9% 4.1% $16M
2011 $2M 4.1% 3.6% $20M

Valuation over time

How the market has priced LMAT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 40.6 81.1 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 6.3 12.6 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S
Dividend yield (%)
0.0 0.5 1.0 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
Dividend yield %

Frequently asked questions

Is LMAT growing its revenue and profit?

Over the past 5 years, Lemaitre Vascular Inc's revenue has grown 14.0% per year, and net income grown 22.1% per year. These are computed facts, not advice.

How much debt does LMAT have?

As of FY2025, Lemaitre Vascular Inc reported — of total debt against $28M of cash; operating income covered interest expense 13×.

What is LMAT's profit margin?

In FY2025, gross margin was 71.5%, operating margin 27.2%, and net margin 23.1%.

What is LMAT's P/E ratio?

As of Sep '26, Lemaitre Vascular Inc traded at a price-to-earnings ratio of about 31.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.